Galson Steven K 4

What Happened

• Steven K. Galson, a non-employee director of BioCryst Pharmaceuticals (BCRX), received automatic equity awards on 2026-06-11: 15,294 restricted stock units (RSUs) and a derivative award covering 33,540 shares (stock options). Both grants show $0.00 as the acquisition price (no cash paid).
• These grants are awards rather than purchases or sales and are part of director compensation rather than an open-market trade.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-15 (timely under the two-business-day rule).
• Awards: 15,294 RSUs (grant) and 33,540-share derivative award (stock options); reported acquisition price $0.00.
• Vesting: The 15,294 RSUs vest on the first anniversary of the grant (per the Director Compensation Policy).
• Ownership after transaction: The filing does not state total shares/options held after these grants.
• Footnotes: F1 = automatic non-employee director RSU grant (vests in one year); F3 = automatic non-employee director stock option grant; F2 notes Galson previously transferred 12,491 shares to a living trust on 2025-07-23 but remains an indirect beneficial owner of those trust-held shares.
• No exercise price, expiration, or immediate sale of awarded shares was disclosed in the filing.

Context

• These awards are routine, automatic director compensation under the company’s policy and are not market purchases or sales. RSUs vest over time; options are a derivative grant (not an exercise). Transfers to a living trust (F2) are a prior non-sale transfer and do not necessarily indicate a change in market sentiment.